糖酵解抑制剂用于抗肿瘤药物的研究进展  

The research progress of glycolysis inhibitors in anti-tumor drugs

作　　者：李奉锦 王东凯[1] LI Fengjin;WANG Dongkai(School of pharmacy,Shenyang Pharmaceutical university,Benxi 117004,China)

机构地区：[1]沈阳药科大学药学院,辽宁本溪117004

出　　处：《中国药剂学杂志（网络版）》2024年第6期234-242,共9页Chinese Journal of Pharmaceutics：Online Edition

摘　　要：目的对糖酵解及基于糖酵解靶点的抗肿瘤药物做一综述。方法通过整理国内外相关文献对糖酵解抑制剂的具体给药系统展开论述。结果和结论糖酵解异常是肿瘤细胞的重要特征,糖酵解靶点抑制剂与其他类型的抗肿瘤药物的联合给药递送系统对肿瘤的抑制作用比单一用药效果更好,这也为肿瘤治疗提供了新的方向。Objective In this paper,glycolysis and anti-tumor drugs based on glycolysis targets are reviewed.Methods The specific drug delivery system of glycolysis inhibitors was discussed by sorting out the relevant literatures at home and abroad.Results and discussion Abnormal glycolysis is an important feature of tumor cells.The combined drug delivery systems of glycolysis target inhibitors and other types of anti-tumor drugs provide a new direction for tumor treatment.

关 键 词：糖酵解 靶点 肿瘤 联合给药 递送系统 

分 类 号：R94[医药卫生—药剂学]